SYT9 Antibody

What is SYT9 and what are its key structural features?

SYT9 (Synaptotagmin-9) is a member of the Synaptotagmin protein family involved in Ca2+-dependent exocytosis of secretory vesicles. In humans, the canonical protein consists of 491 amino acid residues with a molecular mass of approximately 56.2 kDa . The protein contains C2 domains that bind Ca2+ and phospholipids, though with unique properties compared to other synaptotagmins. Specifically, the C2A domain of SYT9 functions as a Ca2+-binding module, but unlike Synaptotagmin-1 (Syt1), the C2B domain does not form Ca2+/phospholipid complexes, which are essential for Syt1 function . SYT9's subcellular localization is primarily in cytoplasmic vesicles .

How does SYT9 differ from other synaptotagmin family members?

SYT9 possesses distinct properties that differentiate it from other synaptotagmins, particularly Syt1:

• Despite sharing 81% sequence identity with Syt1's C2B domain, SYT9's C2B domain does not form Ca2+/phospholipid complexes .

• Endogenous SYT9 does not associate with SNARE protein complexes either Ca2+-dependently or independently, unlike Syt1 .

• SYT9 colocalizes with substance P (SP), a dense-core vesicle peptide hormone in striatal neurons, suggesting specific roles in peptide release .

• While Syt1 is essential for fast Ca2+-triggered exocytosis, SYT9 appears to have distinctive functions in regulating insulin secretion and spontaneous neurotransmitter release .

What are common applications for SYT9 antibodies in research?

SYT9 antibodies are primarily used for:

• Western blot analysis to detect and quantify SYT9 protein expression in various tissues and cell types .

• Immunocytochemistry and confocal microscopy to visualize SYT9 localization and co-localization with other proteins .

• ELISA assays for sensitive quantitation of SYT9 levels in biological samples .

• Immunoprecipitation experiments to study protein-protein interactions involving SYT9 .

• Functional studies using antibody-mediated inhibition to investigate SYT9's role in exocytosis .

How does SYT9 regulate insulin secretion from pancreatic β-cells?

Recent research has revealed that SYT9 plays an inhibitory role in insulin secretion through its interaction with tomosyn-1 and syntaxin-1A (Stx1A). The molecular mechanism involves:

• SYT9 colocalizes and binds with tomosyn-1 and Stx1A at the plasma membrane .

• This Syt9-tomosyn-1-Stx1A complex inhibits SNARE complex formation, thereby rendering insulin granules non-fusogenic .

• Genetic ablation of SYT9 in mice leads to:

  • Reduced tomosyn-1 protein abundance via proteasomal degradation

  • Decreased binding of tomosyn-1 to Stx1A

  • Increased Stx1A-SNARE complex formation

  • Enhanced biphasic and static insulin secretion

  • Improved glucose clearance and elevated plasma insulin levels without affecting insulin action

Interestingly, rescuing tomosyn-1 expression blocks the increased insulin secretion observed in SYT9-knockdown cells, confirming that SYT9's inhibitory effects are mediated through tomosyn-1 .

What is the role of SYT9 in neuronal function and neurotransmitter release?

SYT9's function in neuronal cells appears to be distinct from its pancreatic role. In striatal neurons:

• SYT9 modulates spontaneous neurotransmitter release by regulating substance P (SP) secretion .

• Loss of SYT9 in cultured striatal neurons results in decreased spontaneous miniature synaptic vesicle fusion rate (mini frequency) .

• SYT9 co-localizes with substance P, a dense-core vesicle peptide hormone enriched in striatal neurons .

• Knockout of SYT9 impairs action potential-triggered substance P release .

How do the Ca2+-binding properties of SYT9 differ from other synaptotagmins?

SYT9 exhibits unique Ca2+-binding properties that distinguish it from other synaptotagmins, particularly SYT1:

• While the C2A domain of SYT9 functions as a Ca2+-binding module similar to SYT1, the C2B domain of SYT9 does not form Ca2+/phospholipid complexes that are essential for SYT1 function .

• Despite the high sequence identity (81%) between the C2B domains of SYT9 and SYT1, a few evolutionarily conserved amino acid changes appear to inactivate Ca2+ binding to the C2B domain of SYT9 .

• Unlike SYT1, endogenous SYT9 does not associate with SNARE protein complexes in either a Ca2+-dependent or Ca2+-independent manner .

• These unique properties suggest that SYT9 and SYT1 are Ca2+ sensors with similar Ca2+-binding sequences but distinct properties indicating non-overlapping functions .

What are the best practices for using SYT9 antibodies in Western blot applications?

When using SYT9 antibodies for Western blot applications, researchers should consider:

• Antibody selection: Choose antibodies specifically generated against the linker region separating the transmembrane region from the C2 domains rather than antibodies targeting the C2 domains, as the latter may cross-react with other synaptotagmins due to high sequence homology .

• Sample preparation: For tissue samples, homogenization in appropriate buffers with protease inhibitors is essential to prevent degradation of SYT9 protein.

• Controls: Include positive controls (tissues known to express SYT9) and negative controls (SYT9 knockout samples if available) to validate antibody specificity.

• Detection systems: SuperSignal West Pico Plus Chemiluminescent Substrate has been successfully used for visualizing SYT9 immunoreactive bands .

• Analysis: Perform densitometric analysis to quantify bands, ensuring measurements stay within the linear range of detection .

How can researchers effectively visualize SYT9 localization in cells?

For immunocytochemistry and confocal microscopy to visualize SYT9:

• Fixation and permeabilization: Standard protocols using paraformaldehyde fixation followed by detergent permeabilization are effective .

• Differential labeling strategies: For pH-SYT9 (pHluorin-tagged SYT9) experiments, a two-step labeling approach can be used:

  • First, label only surface-resident pH-SYT9 in live cells using anti-GFP antibodies

  • After fixation and permeabilization, label internal pH-SYT9 with a second anti-GFP antibody

  • Use species-specific secondary antibodies to differentiate between the two populations

• Co-localization studies: Include markers for relevant subcellular compartments (e.g., synaptophysin for synaptic vesicles) to determine SYT9 localization .

• Imaging parameters: Use a high-resolution confocal microscope (e.g., Zeiss LSM 880) with a 63x Plan-Apochromat 1.4NA objective for optimal imaging .

• Consistency: Maintain identical laser and gain settings for all samples within each experimental paradigm to enable valid comparisons .

What approaches can be used to study SYT9 function in cellular models?

To investigate SYT9 function in cellular models, researchers can employ several strategies:

• Genetic manipulation:

  • CRISPR/Cas9-mediated knockout to completely eliminate SYT9 expression

  • RNA interference (siRNA or shRNA) for transient or stable knockdown

  • Overexpression of wild-type or mutant SYT9 to study structure-function relationships

• Functional assays:

  • For β-cells: Glucose-stimulated insulin secretion assays to measure biphasic and static insulin release

  • For neurons: Electrophysiological recordings to measure spontaneous and evoked neurotransmitter release

  • Peptide release assays to quantify substance P secretion in neuronal preparations

• Protein interaction studies:

  • Co-immunoprecipitation to identify SYT9-interacting partners

  • Proximity ligation assays to visualize protein interactions in situ

  • Rescue experiments (e.g., tomosyn-1 rescue in SYT9-knockdown cells) to establish functional relationships

How should researchers interpret contradictory findings regarding SYT9 function?

The literature contains some contradictory findings regarding SYT9 function, particularly in insulin secretion. To navigate these contradictions:

• Consider experimental context: The function of SYT9 may vary depending on cell type, developmental stage, and experimental conditions.

• Expression levels matter: SYT9 can rescue Syt1 knockout phenotypes only when expressed at levels ~25-fold higher than endogenous SYT9, suggesting concentration-dependent effects .

• Methodological differences: Antibody-mediated inhibition studies may produce different results compared to genetic knockout approaches due to possible steric hindrance effects rather than functional inhibition .

• Reconcile with molecular mechanisms: The inhibitory effect of SYT9 on insulin secretion through tomosyn-1 provides a molecular mechanism that differs from previous studies suggesting either a positive or no effect of SYT9 on insulin secretion .

• Future directions: Cell-type specific knockout models (e.g., β-cell-specific SYT9 deletion) will be crucial for definitively establishing SYT9's role in specific tissues .